CASI Pharmaceuticals (NASDAQ:CASI) Releases Earnings Results

CASI Pharmaceuticals (NASDAQ:CASI) posted its quarterly earnings data on Monday. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, Zacks reports. CASI Pharmaceuticals had a negative net margin of 143.18% and a negative return on equity of 181.52%.

CASI Pharmaceuticals Price Performance

Shares of CASI opened at $2.13 on Monday. The firm has a 50-day simple moving average of $2.39 and a two-hundred day simple moving average of $3.85. The company has a debt-to-equity ratio of 1.38, a current ratio of 3.20 and a quick ratio of 2.32. CASI Pharmaceuticals has a 1-year low of $2.04 and a 1-year high of $7.67. The stock has a market cap of $32.92 million, a PE ratio of -0.95 and a beta of 0.41.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of CASI Pharmaceuticals in a research note on Thursday. They issued a “hold” rating on the stock.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.